CluePoints Ships AI Clinical Data Review Tools After Top-10 Pharma Pilot

CluePoints releases AI clinical data review suite after live pharma deployment

CluePoints has made three AI-powered clinical data review capabilities generally available after developing and testing them inside a top-10 pharmaceutical company's active trial portfolio. The tools—Intelligent Query Detection (IQD), Medical and Safety Review (MSR), and Intelligent Medical Coding (IMC)—address persistent bottlenecks in data management workflows that still rely heavily on spreadsheets and manual processes, according to details first reported by Clinical Trial Vanguard.

The deployment model is notable: rather than launching with proof-of-concept pilots, the capabilities are already running across the majority of the unnamed co-innovation partner's ongoing studies, including large-scale trials, at the time of general release.

Why it matters

Clinical data review remains one of the most manual, time-intensive phases of trial operations, with institutional knowledge often lost at each dictionary update or staff transition. Tools that can reduce coding effort by half while maintaining 99% accuracy—and that deploy in days across active studies rather than requiring clean trial starts—directly address cost and timeline pressure points that scale with portfolio size. The timing also aligns with ICH E6(R3) implementation, creating a regulatory tailwind for integrated risk-based quality management approaches.

Three capabilities targeting distinct workflow pain points

Intelligent Query Detection allows data managers to define clinical or operational questions in plain language without writing code or submitting vendor change requests. The system applies that logic continuously and surfaces only records requiring attention.

Medical and Safety Review replaces static spreadsheet reconciliation with a change-based, patient-centric workflow that posts queries directly into the electronic data capture system. This eliminates the handoff between Medical, Safety, and Data Management teams that typically creates the longest delays in review cycles.

Intelligent Medical Coding targets up to 99% accuracy on MedDRA term suggestions and cuts manual coding effort by approximately half. The capability addresses a problem that compounds across portfolios: coding knowledge typically resets with each dictionary version update or team change.

Regulatory context and deployment speed

The release follows finalization of ICH E6(R3) in January 2025, with the EMA making it effective in July 2025 and FDA publication in September 2025. The updated guidance formally encodes risk-based quality management principles that CluePoints' earlier RBQM platform helped establish in practice. Extending the same statistical foundation into query management, medical review, and coding connects a sponsor's data oversight workflow under a single framework the guideline already recognizes.

Medical and Safety Review deploys in days and works across ongoing studies, removing the typical barrier of waiting for new trial initiation. The co-innovation partner's data management leadership will present production results alongside CluePoints at the SCDM 2026 Annual Conference in Raleigh, September 14-17.

Production testing shaped the product

The pharmaceutical partner's teams directly influenced both IQD's user-defined scenario architecture and MSR's change-based review model during development. This co-innovation approach meant the tools were stress-tested against real operational constraints and portfolio diversity before general availability.

Details of the launch were first reported by Clinical Trial Vanguard.